Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.
Gastrointestinal Stromal Tumors
DRUG: Famitinib capsules|DRUG: Sunitinib Capsules
Progression-free survival (PFS), Progression-free survival (PFS) assessed by BIRC based on RECIST 1.1 criteria, 30 months
Progression-free survival (PFS), Progression-free survival (PFS) assessed by BIRC based on mRECIST criteria, 30 months|Progression-free survival (PFS), Progression-free survival (PFS) assessed by researchers based on RECIST 1.1 criteria, 30 months|time to disease progression (TTP), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: time to disease progression (TTP), 30 months|Time to treatment failure (TTF), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: Time to treatment failure (TTF);, 30 months|Objective response rate (ORR), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: Objective response rate (ORR), 30 months|Duration of Response (DOR), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: Duration of Response (DOR), 30 months|Disease control rates (DCR), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: Disease control rates (DCR), 30 months|overall survival (OS), Based on the RECIST v1.1 criteria, BIRC and the researchers' evaluation of: overall survival (OS), 30 months|Adverse Events and Serious Adverse Events, Adverse Events and Serious Adverse Events, 30 months
The study is being conducted to evaluate the efficacy and safety of famitinib in the treatment of advanced gastrointestinal stromal tumour patients after failure of imatinib compared to sunitinib.